Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy

Hepatitis C, Chronic Clinical Trial

Official title:

Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03903185
• Other study ID #: CL 3062
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: March 1, 2019
• Est. completion date: August 15, 2023

Study information

• Verified date: August 2023
• Source: Ain Shams University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, controlled, open-label, pharmacokinetic study. This study aims at studying the PK of ledipasvir, sofosbuvir, and GS-331007 metabolite in HCV infected children with hematological malignancy.

In this study, patients in both treatment groups will receive 12 weeks of treatment with a fixed-dose combination tablet containing 45 mg of ledipasvir and 200 mg of sofosbuvir (LDV/SOF) orally, once daily with food.

Description:

In this study, patients in both treatment groups will receive 12 weeks of treatment with a fixed-dose combination tablet containing 45 mg of ledipasvir and 200 mg of sofosbuvir (LDV/SOF) orally, once daily with food, as prescribed by the attending physician.

Twelve eligible HCV-infected patients with hematological malignancy and 12 matching HCV control patients without haematological malignancy or co-morbidities will be enrolled in the study.

At baseline, careful history of the recruited patients including demographic characteristics (age, height, weight, and gender), comorbidities, medication history, familial history, social history, blood transfusion history, time on maintenance chemotherapy, and baseline laboratory tests will be documented. The baseline laboratory tests will include renal function tests (serum creatinine), liver function tests (bilirubin, albumin, AST, and ALT), international normalized ratio (INR), alpha fetoprotein (AFP), complete blood count (CBC), degree of liver fibrosis by Fibroscan, and viral load by PCR.

Followup will be done for all participants at baseline, after 12 weeks of treatment, and after 12 weeks from the end of treatment. A Forth visit will be done after 10 days of treatment for the evaluation of the steady state PK parameters of LDV\SOF in those patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: August 15, 2023
• Est. primary completion date: July 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 12 Years

Eligibility

Inclusion Criteria:

• Children (6 to < 12 years of age and/or weighing 17.5 to < 35 Kg).

• Chronic HCV genotype 4 infection for at least 6 months without cirrhosis (confirmed by Fibroscan).

• Naïve patients to previous anti-HCV treatment.

• Diagnosed with hematological malignancy and on maintenance chemotherapy.

Exclusion Criteria:

• Known hypersensitivity to any of the study medications.

• Ongoing treatment with any interacting medications like carbamazepine, fosphenytoin, phenytoin, oxcarbazepine, phenobarbital, and rifampin.

• History of any comorbid illness that may interfere with the pharmacokinetics of the study drugs or prohibit the compliance with the study protocol such as;

1. Decompensated liver disease as shown by the presence of ascites, encephalopathy, or a history of variceal hemorrhage.

2. The ongoing treatment of other types of cancer or blood disorders.

3. Co-infection with human immunodeficiency virus (HIV), or hepatitis B virus.

4. Renal dysfunction.

5. Active infection that is currently producing symptoms.

Related Conditions & MeSH terms

• Hematologic Malignancy
• Hematologic Neoplasms
• Hepatitis
• Hepatitis A
• Hepatitis C
• Hepatitis C, Chronic
• Neoplasms

Intervention

Drug:
• Ledipasvir / Sofosbuvir Oral Product
45 mg of ledipasvir and 200 mg of sofosbuvir orally, once daily with food

Locations

Country	Name	City	State
Egypt	Faculty of Medicine Ain Shams Research Institute- Clinical Research Center (MASRI-CRC)	Cairo	Al Qahirah
Egypt	Pediatric Hematology Oncology and BMT Department, Faculty of Medicine, Ain Shams University	Cairo

Sponsors (2)

Lead Sponsor	Collaborator
Ain Shams University	Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of the pharmacokinetics of LDV\SOF	After 10 days of treatment, the steady state for LDV/SOF will be reached. Serial blood samples (2 mL/sample) will be collected at this time for the determination of LDV/SOF and GS-331007 concentrations from patients using an eight-point plasma schedule.; Blood sampling schedule will be as follows (Predose, 0.5,1, 2, 3, 4, 8, and 12h post dose; with predose also serving as t = 24).; Any deviations from nominal sampling times will be accurately recorded.	Blood samples will be collected after 10 days of treatment
Secondary	Measurement of the number of participants with sustained virological response (SVR12), 12 weeks after discontinuation of therapy with ledipasvir-sofosbuvir (LDV-SOF).	Number of Participants with sustained virological response at 12 Weeks after end of study drug treatment (SVR12) will be recorded.; Participant will be considered to have achieved SVR12 if HCV RNA is less than the lower limit of quantification of <15 IU/ml) at 12 weeks after the end of treatment.	12 weeks after discontinuation of therapy with ledipasvir-sofosbuvir (LDV\SOF)